Results 221 to 230 of about 280,456 (250)

Low Density Lipoprotein Apheresis

2013
Therapeutic plasma exchange volume is usually 3–5 L/session. Removal of positively charged particles as well as low density lipoprotein cholesterol improves focal segmental glomerulosclerosis and peripheral arterial disease. Angiotensin converting enzyme (ACE) inhibitors should be discontinued at least 2–3 days prior to low density ...
Kenjiro Honda, Kent Doi
openaire   +1 more source

Vascular access in lipoprotein apheresis: a retrospective analysis from the UK’s largest lipoprotein apheresis centre

The Journal of Vascular Access, 2018
Introduction: Lipoprotein apheresis (LA) has proven to be an effective, safe and life-saving therapy. Vascular access is needed to facilitate this treatment but has recognised complications. Despite consistency in treatment indication and duration there are no guidelines in place. The aim of this study is to characterise vascular access practice at the
Daniel J, Doherty, Alison, Pottle, George, Malietzis, Nadey, Hakim, Mahmoud, Barbir, Jeremy S, Crane   +5 more
openaire   +2 more sources

Low-density lipoprotein apheresis therapy during pregnancy

The American Journal of Cardiology, 2000
Pregnancy in patients with severe hypercholesterolemia and coronary artery disease results in multiple problems both for mother and fetus; the most potent agents for low-density lipoprotein (LDL) cholesterol reduction, the HMG-CoA reductase inhibitors (statins) cannot be used during pregnancy.
L, Cashin-Hemphill, M, Noone, J F, Abbott, C A, Waksmonski, R S, Lees   +4 more
openaire   +2 more sources

Differential Indication of Lipoprotein Apheresis During Pregnancy

Therapeutic Apheresis and Dialysis, 2003
Abstract: Lipoprotein apheresis is an effective treatment for severe disorders of lipid metabolism. It is the only life prolonging therapy for patients with homozygous familial hypercholesterolemia. Changes of lipid metabolism during pregnancy related to changes of hormone concentrations do not cause clinical complications in the majority of cases ...
Reinhard, Klingel, Britta, Göhlen, Andreas, Schwarting, Frido, Himmelsbach, Richard, Straube   +4 more
openaire   +2 more sources

Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand

Journal of clinical apheresis, 2020
Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid‐lowering therapies.
M. M. Page, E. Ekinci, J. Burnett, A. Hooper, N. Reid, W. Bishop, C. Florkowski, R. Scott, R. O’Brien, G. Watts   +9 more
semanticscholar   +1 more source

Complement Activation During Low‐Density Lipoprotein Apheresis

Artificial Organs, 1992
Abstract: Complement system activation was investigated in two girls with familial homozygous hypercholes‐terolemia undergoing two monthly sessions on LA15 or LA40 (Kaneka liposorber). We determined blood levels of C3c and C3a, leukocyte counts, and plasma levels of C3c and C3a in the extracorporeal circulation device at the start of the sessions and ...
A, Tridon, J B, Palcoux, P, Jouanel, M J, Bezou, M, Coulet, G, Betail   +5 more
openaire   +2 more sources

History of lipidology and lipoprotein apheresis

Atherosclerosis Supplements, 2017
This review tells the story of atherosclerosis research in the beginning of the 20th century. It presents the significance of cardiovascular diseases and addresses major questions currently being discussed among lipidologists and the current thinking with respect to low LDL-cholesterol levels and HDL.
openaire   +2 more sources

Effects of lipoprotein apheresis on PCSK9 levels

Atherosclerosis Supplements, 2015
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) increases LDL cholesterol (LDL-C) levels by stimulating the degradation of Low Density Lipoprotein receptors (LDL-r). This protein is now of high interest because antibodies which inhibit its effect on LDL-r are being developed.
U, Julius, M, Milton, D, Stoellner, D, Rader, B, Gordon, D, Polk, E, Waldmann, K G, Parhofer, P M, Moriarty   +8 more
openaire   +2 more sources

Current situation of lipoprotein apheresis in Saxony

Atherosclerosis Supplements, 2013
This paper summarizes the situation pertinent to treatment via lipoprotein apheresis in the federal state of Saxony, Germany in 2010. In total, 119 predominately male patients were treated in 10 centers; the majority of the patients was older than the mean age of the general population.
U, Julius, K, Taseva, S, Fischer, J, Passauer, S R, Bornstein   +4 more
openaire   +2 more sources

Role of Low-Density Lipoprotein Apheresis

The American Journal of Cardiology, 2005
Low-density lipoprotein (LDL) apheresis has been shown to reduce plasma levels of total cholesterol, LDL cholesterol, and lipoprotein(a). In addition to these lipoprotein changes, LDL apheresis induces atherosclerosis regression, improves myocardial perfusion and endothelial function, and may reduce cardiovascular event rates.
openaire   +2 more sources